Evernorth announces biosimilar Humira available at $0 out-of-pocket for Accredo patients in June

  • There will be interchangeable high and low concentration biosimilars, estimated to save individual patients $3,500 on average per year
  • The price of biosimilars will be approximately 85% lower than Humira*

BLOOMFIELD, Conn., April 25, 2024 /PRNewswire/ — In an important step to drive long-term affordability and access to treatments for chronic and complex conditions, Evernorth Health Services announced that it will have a Humira biosimilar available for $0 out of pocket for eligible patients of your Accredo specialty pharmacy starting this June. The high- and low-strength interchangeable biosimilar will be produced for Evernorth’s affiliated private label pharmaceutical distributor, Quallent Pharmaceuticals, through multi-manufacturer agreements. It will be available at $0 out-of-pocket for most patients through Quallent’s co-pay assistance program. This program is estimated to save individual patients $3,500 on average per year.

“Biosimilars can help generate significant savings for patients and their health plans now and in the future. To help achieve these savings, it’s important to ensure that patients are supported and their experience is seamless,” he said. to say. Matt Perlberg, president of Evernorth Health Services’ pharmacy and care delivery businesses. “Because of the leadership capabilities we have at Evernorth and throughout the supply chain, we are uniquely positioned to make patient experiences as simple as possible.”

The price of the biosimilar will be approximately 85% lower than the list price for Humira. For many employers, unions, municipalities and other health plan sponsors who choose to work with Accredo as part of their specialty pharmacy network offering, this represents a significant savings opportunity.

More than 100,000 Accredo patients are currently using Humira or one of its biosimilars, with the support of pharmacists and nurses with specialized training at the Accredo Therapeutic Resource Center for inflammatory conditions. Accredo’s 15 dedicated therapeutic resource centers connect patients with pharmacists and nurses 24/7, helping to ensure patients receive care from doctors who specialize in their condition and take their time to understand their circumstances.

“Patients living with an inflammatory disease like Crohn’s disease or rheumatoid arthritis often navigate multiple medications prescribed by different doctors,” he said. Susan Peppers, RPh, vice president of pharmacy practice at Evernorth. “Accredo helps them manage everything around their specialty medicine, from working with their doctors, advising on their therapy and administering their medications to coordinating copay assistance and working with the patient’s health plan to ensure coverage Last year alone, we helped patients save almost 2.8 billion dollars by connecting them with copay assistance programs, and we look forward to helping patients save even more this year.”

About Evernorth Health Services
Evernorth Health Services creates pharmacy, care and benefit solutions to improve health and increase vitality. We innovate relentlessly to make the prediction, prevention and treatment of disease and illness more accessible to millions of people. Evernorth’s capabilities are powered by our companies, including Express Scripts, Express Scripts Pharmacy, Accredo, eviCore and MDLIVE, along with Evernorth’s holistic platforms and solutions that move people and organizations forward. All Evernorth Solutions are serviced and provided by or through Evernorth Health’s operating subsidiaries, a wholly owned subsidiary of The Cigna Group (NYSE: CI) or third party partners. Learn more at evernorth.com.

Contact with the media
Justine Sessions
[email protected]

*Humira is a product of AbbVie.

SOURCE Evernorth Health Services

#Evernorth #announces #biosimilar #Humira #outofpocket #Accredo #patients #June
Image Source : www.prnewswire.com

Leave a Comment